Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 6/20 | 0.50 |
| ▸ | HRH1 | P35367 | 6/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611407 | 0.98 | HRH3 (0.51) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL15810293 | 0.94 | MMP2 (0.58) | HRH3HRH2HRH1MMP2MMP3 | |
| SCHEMBL1713933 | 0.94 | ALDH1A1 (0.54) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL3107072 | 0.92 | HRH3 (0.57) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL22401643 | 0.92 | HRH3 (0.57) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL11031564 | 0.92 | HRH3 (0.57) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL1999659 | 0.92 | HRH3 (0.57) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL14448890 | 0.92 | HRH3 (0.57) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL5522642 | 0.92 | HRH3 (0.57) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL1018896 | 0.89 | ALDH1A1 (0.53) | HRH3MAPTALDH1A1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388581-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250312340-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. | 2025-10-09 | — | — | US | disclosed |
| US-12331052-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240415832-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-12-19 | — | — | US | disclosed |
| EP-4419523-A1 | NOVEL METHODS | Intra-Cellular Therapies, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556058-A | New method | 细胞内治疗公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118105390-A | Method for treating addiction | 细胞内治疗公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023069880-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20220184072-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220088014-A1 | METHODS OF TREATING ADDICTION | INTRA-CELLULAR THERAPIES, INC. | 2022-03-24 | — | — | US | disclosed |
| US-5877174-A | ANTICOAGULANTS | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-03-02 | — | — | US | disclosed |
| EP-0485965-B1 | Photographic silver halide material and process | EASTMAN KODAK CO (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0805149-A1 | NOVEL 2,3-DIKETOPIPERAZINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-11-05 | — | — | EP | disclosed |
| EP-0403019-B1 | Photographic material and process | EASTMAN KODAK CO (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5135839-A | Coupler mixture | EASTMAN KODAK COMPANY (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0485965-A1 | Photographic silver halide material and process | EASTMAN KODAK COMPANY (US) | 1992-05-20 | — | — | EP | disclosed |
| US-5006448-A | Containing compound capable of releasing development inhibitor | EASTMAN KODAK COMPANY (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0403019-A2 | Photographic material and process | EASTMAN KODAK COMPANY (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0111345-A2 | Isoxazoles, useful as antiviral agents, and preparation thereof | STERLING DRUG INC. (US) | 1984-06-20 | — | — | EP | disclosed |
| US-4451476-A | Isoxazoles as antiviral agents | STERLING DRUG INC. (US) | 1984-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312340-A1 | METHODS OF TREATING NEUROPATHIC PAIN | GAP43, OPRK1, CNR2 | HRH3 276/4885MAPT 1091/4885ALDH1A1 1202/4885 |
| US-20250388581-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | HRH3 238/4885MAPT 1426/4885ALDH1A1 943/4885 |
| US-12331052-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | HRH3 386/4885MAPT 1448/4885ALDH1A1 942/4885 |
| US-20240415832-A1 | NOVEL METHODS | OPRK1, OPRD1, OPRM1 | HRH3 249/4885MAPT 4104/4885ALDH1A1 872/4885 |
| US-20220088014-A1 | METHODS OF TREATING ADDICTION | OPRK1, OPRM1, OPRD1 | HRH3 254/4885MAPT 1740/4885ALDH1A1 322/4885 |
| US-20220184072-A1 | METHODS OF TREATING NEUROPATHIC PAIN | GAP43, OPRK1, CNR2 | HRH3 276/4885MAPT 1091/4885ALDH1A1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.